Synopsis: Blue Jet Healthcare raised ₹800 crore through a QIP, with Shamyak Investment and ICICI Prudential Mutual Fund receiving over 68% of the issue, reinforcing investor confidence and supporting future expansion.
This Small-cap Healthcare Stock, engaged in the manufacturing of pharmaceutical intermediates, contrast media intermediates, active pharmaceutical ingredients (APIs), and specialty healthcare products for global pharmaceutical companies, is in focus after allotting 68.13 percent of its Rs. 800 crore QIP to ICICI Prudential MF and Shamyak Investment.
With a market capitalization of Rs. 10,500.73 crores, the share of Blue Jet Healthcare Limited has reached an intraday high of Rs. 624.90 per equity share, rising nearly 8.72 percent from its previous day’s close price of Rs. 574.80. Since then, the stock has retreated and is currently trading at Rs. 605.35 per equity share.
Reason Behind the Surge:
Blue Jet Healthcare Limited has successfully completed its Qualified Institutional Placement (QIP) by allotting 1,58,10,276 equity shares to eligible institutional investors. The shares were issued at Rs. 506 per share, which is a premium of Rs. 504 per share compared to face value, with a 4.83 percent discount to the floor price. Through this issue, the company raised Rs. 8,000 million (Rs. 800 crore) to support its growth plans.
Following the allotment, the company’s paid-up equity share capital increased from 17,34,65,425 shares to 18,92,75,701 shares. The QIP opened on July 6, 2026, and closed on July 9, 2026. The issue received participation from several leading institutional investors, reflecting confidence in the company’s future prospects.
Among the investors, Shamyak Investment Private Limited received 54,34,785 shares, accounting for 34.38 percent of the total issue. Various ICICI Prudential Mutual Fund schemes together were allotted 53,35,974 shares, representing 33.75 percent of the issue. The successful fundraising is expected to strengthen Blue Jet Healthcare’s financial position and support its long-term expansion plans.
Growth Strategy:
Blue Jet Healthcare Limited is focused on expanding its business through operational efficiency, innovation, and capacity growth. The company continues to invest in research and development (R&D) to strengthen its product capabilities and improve manufacturing processes. It is also increasing production capacity to meet rising customer demand while reducing supply chain risks through better operational planning.
The company aims to move into higher-value pharmaceutical intermediates, especially for contrast media, and expand its presence in the pharma intermediates and active pharmaceutical ingredients (API) business. By leveraging its long-term customer relationships and strategic investments, Blue Jet Healthcare plans to achieve sustainable growth and strengthen its position in the pharmaceutical industry.
Key Business Segments:
Blue Jet Healthcare Limited manufactures contrast media intermediates, specialty pharmaceutical intermediates, and active pharmaceutical ingredients (APIs). The company also provides CDMO/CMO services, helping pharmaceutical companies develop and manufacture complex medicines at a commercial scale.
Company Overview:
Blue Jet Healthcare Limited is an Indian specialty pharmaceutical company that develops and manufactures pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and related products for global pharmaceutical customers. Founded in 1968, it has evolved into a science-driven manufacturer with a strong presence in niche, high-value product categories and serves customers across India, Europe, the United States, and other international markets.
Recent Quarter Results:
Coming into financial highlights, Blue Jet Healthcare Limited’s revenue has decreased from Rs. 340 crore in Q4 FY25 to Rs. 235 crore in Q4 FY26, which is a drop of 30.88 percent. The net profit has also decreased by 41.82 percent from Rs. 110 crore in Q4 FY25 to Rs. 64 crore in Q4 FY26. Blue Jet Healthcare Limited’s revenue and net profit have grown at a CAGR of 14 percent and 12 percent, respectively, over the last five years.
In terms of return ratios, the company’s ROCE and ROE stand at 26.5 percent and 19.9 percent, respectively. Blue Jet Healthcare Limited has an earnings per share (EPS) of Rs. 14.3, and its debt-to-equity ratio is 0.03x.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
